Key facts
- This page summarizes Christopher Yea's Form 4 filing for KalVista Pharmaceuticals, Inc. (KALV).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 Aug 2024, 19:58.
Christopher Yea - 22 Aug 2024 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)
- Reporting relationship
- CHIEF DEVELOPMENT OFFICER
- Issuer ticker
- KALV
- Reported as of
- 22 Aug 2024
- Net transaction value
- -$23,758
- SEC form
- 4
- Accepted by SEC
- 26 Aug 2024, 19:58:40 UTC
- Prior SEC filing
- 21 Aug 2024
- Next SEC filing
- 19 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Benjamin L. Palleiko, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Yea filed Form 4 for KalVista Pharmaceuticals, Inc. (KALV) on 26 Aug 2024.
Change
- Previous filing in this sequence was filed on 21 Aug 2024.
- Current net transaction value: -$23,758.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KALV
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,125
- Change %
- +3.7%
- Price
- Shares after
- 87,592
- Date
- 22 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
KALV
transaction
Common Stock
Sale
- Transaction value
- $23,758
- Shares
- -1,916
- Change %
- -2.2%
- Price
- $12.40
- Shares after
- 85,676
- Date
- 23 Aug 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KALV
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -3,125
- Change %
- -6.2%
- Price
- $0.000000
- Shares after
- 46,875
- Date
- 22 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,125
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Footnote F2
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Footnote F3
1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.